The news directly pertains to Sage Therapeutics as Mizuho has maintained a Neutral rating on the company and raised the price target. This suggests that Mizuho sees potential in the company but is not overly bullish, hence the neutral score. The raised price target could lead to increased investor interest, but the neutral rating tempers the potential impact.